Back to Awarded Treatment Trials
Awarded Trial: 00-093
Grant ID
00-093
Illness
Schizophrenia
Primary Drug/Intervention
Cannabidiol
Primary Dosage
up to 800g/day
Secondary Drug Intervention
Amilsupiride
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Leweke
Sample Size
70
Duration of Study Period for Each Subject
4 weeks
Outcome Measurements
8PRS, PANSS
Results
Thirty-nine patients completed the four-week trial, or the two-week period necessary for data analysis. Both amisulpiride and cannabidiol produced significant reductions in positive, negative and general symptoms. Cannabidiol did not cause extrapyramidal side effects, weight gain, or prolactin elevation.
Publication
Transl Psychiatry. 2012 Mar 20;2:e94. doi: 10.1038/tp.2012.15. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Leweke FM1, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D.
Link
http://www.ncbi.nlm.nih.gov/pubmed/22832859
PI Name
Franz-Markus Leweke
Degree
MD
Center
Department of Psychiatry and Psychotherapy
Institution
Klinikum der Unversitaet zu Koeln
Address
Kerpener Str. 62
City or Town
Koeln
State or Province
N/A
Zip or Postal Code
50937
Country
Germany
Email Address
m.leweke@uni.de